4/A//SEC Filing
Valor IV Pharma Holdings, LLC 4/A
Accession 0000899243-20-024369
CIK 0001802665other
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 5:19 PM ET
Size
26.8 KB
Accession
0000899243-20-024369
Insider Transaction Report
Form 4/AAmended
Valor Equity Capital IV LLC
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2020-08-21−75,000,000→ 0 total→ Common Stock (10,139,645.04 underlying) - Conversion
Series C Preferred Stock
2020-08-21−1,786,985→ 0 total→ Common Stock (233,052.23 underlying) - Conversion
Common Stock
2020-08-21+10,139,645→ 10,984,981 total - Conversion
Common Stock
2020-08-21+233,052→ 11,218,033 total
Valor Equity Associates IV L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-08-21+233,052→ 11,218,033 total - Conversion
Common Stock
2020-08-21+10,139,645→ 10,984,981 total - Conversion
Series A Preferred Stock
2020-08-21−75,000,000→ 0 total→ Common Stock (10,139,645.04 underlying) - Conversion
Series C Preferred Stock
2020-08-21−1,786,985→ 0 total→ Common Stock (233,052.23 underlying)
VALOR EQUITY PARTNERS IV-B L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-08-21+233,052→ 11,218,033 total - Conversion
Series A Preferred Stock
2020-08-21−75,000,000→ 0 total→ Common Stock (10,139,645.04 underlying) - Conversion
Common Stock
2020-08-21+10,139,645→ 10,984,981 total - Conversion
Series C Preferred Stock
2020-08-21−1,786,985→ 0 total→ Common Stock (233,052.23 underlying)
Gracias Antonio J.
Director
Transactions
- Conversion
Series A Preferred Stock
2020-08-21−75,000,000→ 0 total→ Common Stock (10,139,645.04 underlying) - Conversion
Series C Preferred Stock
2020-08-21−1,786,985→ 0 total→ Common Stock (233,052.23 underlying) - Conversion
Common Stock
2020-08-21+10,139,645→ 10,984,981 total - Conversion
Common Stock
2020-08-21+233,052→ 11,218,033 total
Sabater Juan A.
Director
Transactions
- Conversion
Series C Preferred Stock
2020-08-21−1,786,985→ 0 total→ Common Stock (233,052.23 underlying) - Conversion
Series A Preferred Stock
2020-08-21−75,000,000→ 0 total→ Common Stock (10,139,645.04 underlying) - Conversion
Common Stock
2020-08-21+10,139,645→ 10,984,981 total - Conversion
Common Stock
2020-08-21+233,052→ 11,218,033 total
Valor IV Pharma Holdings, LLC
10% Owner
Transactions
- Conversion
Common Stock
2020-08-21+10,139,645→ 10,984,981 total - Conversion
Series A Preferred Stock
2020-08-21−75,000,000→ 0 total→ Common Stock (10,139,645.04 underlying) - Conversion
Series C Preferred Stock
2020-08-21−1,786,985→ 0 total→ Common Stock (233,052.23 underlying) - Conversion
Common Stock
2020-08-21+233,052→ 11,218,033 total
Valor Management L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-08-21+233,052→ 11,218,033 total - Conversion
Series A Preferred Stock
2020-08-21−75,000,000→ 0 total→ Common Stock (10,139,645.04 underlying) - Conversion
Series C Preferred Stock
2020-08-21−1,786,985→ 0 total→ Common Stock (233,052.23 underlying) - Conversion
Common Stock
2020-08-21+10,139,645→ 10,984,981 total
VALOR EQUITY PARTNERS IV L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-08-21+10,139,645→ 10,984,981 total - Conversion
Common Stock
2020-08-21+233,052→ 11,218,033 total - Conversion
Series A Preferred Stock
2020-08-21−75,000,000→ 0 total→ Common Stock (10,139,645.04 underlying) - Conversion
Series C Preferred Stock
2020-08-21−1,786,985→ 0 total→ Common Stock (233,052.23 underlying)
VALOR EQUITY PARTNERS IV-A L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-08-21+10,139,645→ 10,984,981 total - Conversion
Series C Preferred Stock
2020-08-21−1,786,985→ 0 total→ Common Stock (233,052.23 underlying) - Conversion
Common Stock
2020-08-21+233,052→ 11,218,033 total - Conversion
Series A Preferred Stock
2020-08-21−75,000,000→ 0 total→ Common Stock (10,139,645.04 underlying)
Footnotes (4)
- [F1]Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash.
- [F2]Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein.
- [F3]Includes 1,010,004.14 shares of common stock received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020.
- [F4]Includes 15,525.15 shares of common stock received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020.
Documents
Issuer
Harmony Biosciences Holdings, Inc.
CIK 0001802665
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001821186
Filing Metadata
- Form type
- 4/A
- Filed
- Sep 3, 8:00 PM ET
- Accepted
- Sep 4, 5:19 PM ET
- Size
- 26.8 KB